potassium phosphate, dibasic; potassium phosphate, monobasic · Fresenius Kabi Usa · NDA 212832, 218343
Potassium Phosphates In 0.9% Sodium Chloride
Earliest generic entry, as listed · earliest of 3 marketed strengths
12 Oct 2041
Blocked by patent: US 11813291, US 11925661.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11813291 | drug product, use U-4185 · sets the listed date | 12 Oct 2041 |
| US 11925661 | drug product, use U-4185 · sets the listed date | 12 Oct 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212832 · 004 · RLD | solution, intravenous | 1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) | 12 Oct 2041 |
| 212832 · 005 · RLD | solution, intravenous | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | 12 Oct 2041 |
| 218343 · 001 · RLD | solution, intravenous | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | 12 Oct 2041 |